WO2023143184A1 - Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau - Google Patents
Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau Download PDFInfo
- Publication number
- WO2023143184A1 WO2023143184A1 PCT/CN2023/072356 CN2023072356W WO2023143184A1 WO 2023143184 A1 WO2023143184 A1 WO 2023143184A1 CN 2023072356 W CN2023072356 W CN 2023072356W WO 2023143184 A1 WO2023143184 A1 WO 2023143184A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- ergothioneine
- improving
- photoaging
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000009759 skin aging Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000002028 premature Effects 0.000 title description 3
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 42
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 35
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 19
- 230000008845 photoaging Effects 0.000 claims abstract description 19
- 230000000699 topical effect Effects 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 238000004140 cleaning Methods 0.000 claims description 10
- 230000037303 wrinkles Effects 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 230000037394 skin elasticity Effects 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 230000003467 diminishing effect Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000037393 skin firmness Effects 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000144927 Aloe barbadensis Species 0.000 claims description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims description 3
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims description 3
- 229940117895 bakuchiol Drugs 0.000 claims description 3
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims description 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 3
- 229950011318 cannabidiol Drugs 0.000 claims description 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000002884 skin cream Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 229940111630 tea tree oil Drugs 0.000 claims description 3
- 239000010677 tea tree oil Substances 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- GVQNHIYBRMFCMS-QMMMGPOBSA-N S-methyl-L-ergothioneine Chemical compound CSC1=NC=C(C[C@@H](C([O-])=O)[N+](C)(C)C)N1 GVQNHIYBRMFCMS-QMMMGPOBSA-N 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- CQVZBTBSURUDKC-YDALLXLXSA-M [(2s)-3-(1-ethoxycarbonyl-2-ethoxycarbonylsulfanylimidazol-4-yl)-1-methoxy-1-oxopropan-2-yl]-trimethylazanium;iodide Chemical compound [I-].CCOC(=O)SC1=NC(C[C@@H](C(=O)OC)[N+](C)(C)C)=CN1C(=O)OCC CQVZBTBSURUDKC-YDALLXLXSA-M 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000005722 itchiness Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- RRTOEEXBIOEGRQ-ZETCQYMHSA-N methyl (2s)-2-(dimethylamino)-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoate Chemical compound COC(=O)[C@@H](N(C)C)CC1=CNC(=S)N1 RRTOEEXBIOEGRQ-ZETCQYMHSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 230000036548 skin texture Effects 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 206010040880 Skin irritation Diseases 0.000 abstract description 6
- 230000036556 skin irritation Effects 0.000 abstract description 6
- 231100000475 skin irritation Toxicity 0.000 abstract description 6
- 239000000047 product Substances 0.000 description 10
- 230000032683 aging Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000004909 Moisturizer Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
Definitions
- One aspect of the invention relates to a topical composition, comprising at least one ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof, for preventing or treating skin aging, particularly, premature aging.
- Another aspect of the invention relates to a method for treating skin aging, comprising topical application of the composition of the invention. This topical composition has been reported to rarely produce skin irritation.
- Skin is the main barrier that segregate our body from the outer environment and protects us against environmental stressors. However, like other human organs, skin is also subject to the aging process. Skin aging is a complex biological phenomenon, influenced by both intrinsic factors (e.g., genetics, cellular metabolism, hormone environment) and extrinsic factors (e.g., chemicals, toxins, pollutants, ultraviolet (UV) , and ionizing radiation) , and affecting different constituents of the skin.
- intrinsic factors e.g., genetics, cellular metabolism, hormone environment
- extrinsic factors e.g., chemicals, toxins, pollutants, ultraviolet (UV) , and ionizing radiation
- Intrinsic aging is an inevitable, genetically determined process that affects unexposed and exposed skin and is characterized by dryness, laxity, fine wrinkles, and skin atrophy, while extrinsic aging is engendered by external environment factors such as air pollution, smoking, poor nutrition, and sun exposure, resulting in coarse wrinkles, loss of elasticity, laxity, and rough ⁇ textured appearance (Cell Transplant. 2018 May; 27 (5) : 729–738) . While many external factors could contribute to skin aging, ultraviolet (UV) radiation from sunlight is the primary factor of extrinsic skin aging, also referred to as premature skin aging or photoaging. UV irradiation can induce non ⁇ genomic signal transduction.
- UV ultraviolet
- ROS reactive oxygen species
- Photoaging can be controlled to an extent as it is a result of external factors. Photoaging affects the sun ⁇ exposed areas and is characterized clinically by fine and coarse wrinkling, roughness, dryness, laxity, and pigmentary changes. There is also an increase in development of benign and malignant neoplasms on photoaged skin (Journal of the American Academy of Dermatology, Volume 49, Issue 4, October 2003, Pages 690 ⁇ 697) . The anti ⁇ aging strategies to combat skin aging signs and dysfunction have been developed over the last decades. As people’s cosmetic requirements increase, more research efforts are conducted to help relieving skin aging or preventing of extrinsic aging from occurring.
- Ergothioneine is a naturally occurring, sulfur ⁇ containing amino acid, and is presumed to function as a natural antioxidant. It is mainly found in mushrooms, but also in king crab, and animals that have grazed on grasses containing ergothioneine. Since humans or other vertebrates are unable to synthesize ergothioneine, it can only be acquired by diet. Studies in animals and humans have found no toxicity or adverse effects to be associated with ergothioneine administration, even at high doses. Recently, ergothioneine (Tetrahedron, Paris, France) has attained European Food Safety Authority approval as a Novel Food in the European Union and is generally recognized as a safe supplement and food ingredient by the Food and Drug Administration in the US (GRAS notice No. 734) (FEBS Letters 592 (2016) 3357–3366) .
- Applicants of the present invention have investigated the safety and efficacy of a composition comprising ergothioneine on alleviating skin aging, and provided a topical composition comprising at least one ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof, which can counteract or delay skin aging signs in a safe and effective way.
- This topical composition has been reported to rarely produce skin irritation.
- This invention generally relates to compositions for preventing or improving skin aging, containing at least an active compound which is ergothioneine, an analog, derivative, or dermatologically acceptable salt thereof. Additionally, this invention also relates to a topical application of the composition of the invention to an area of the skin for preventing or treating of damages to skin, particularly, skin damages resulting from premature aging (also known as photoaging) .
- compositions for preventing or treating skin aging comprising at least one compound selected from the group consisting of ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof.
- ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof is present in an amount ranging from 0.01 to 20 %by weight (w/w) , 0.01 to 15 %by weight (w/w) , or 0.01 to 12 %by weight (w/w) .
- ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof is present in an amount of 10%by weight (w/w) . In some other embodiments, ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof, is present in an amount of 0.5 %by weight (w/w) .
- the analog or derivative of ergothioneine is selected from the group consisting of S ⁇ Methyl ⁇ L ⁇ Ergothioneine, N ⁇ Desmethyl L ⁇ Ergothioneine Methyl Ester, N(Im) ⁇ Ethoxycarbonyl ⁇ S ⁇ ethoxycarbonyl L ⁇ Ergothioneine Methyl Ester Iodide, N ⁇ Desmethyl L ⁇ Ergothioneine ⁇ D6 Methyl Ester, L ⁇ (+) ⁇ Ergothioneine ⁇ D3, ergothioneine sulfonate, and L ⁇ Ergothioneine Hydrochloride.
- ergothioneine is L ⁇ ergothioneine.
- the composition further comprises at least one additional agent.
- additional agent include, but not limited to, growth factor, Hyaluronic Acid, Retinol/Retinoic acid, Hydrolyzed Collagen/Collagen Peptides, Vitamin C, Vitamin E, Cannabidiol, EGCG/Green tea, Polyhydroxy Acids , Glycolic Acid , Aloe vera , Niacinamide , Resveratrol , Superoxide dismutase , Tea tree oil , Bakuchiol , Grapeseed oil , Petroleum jelly , and squalene.
- growth factors are, but not limited to, EGF, FGF, NGF, PDGF, VEGF, IGF, GMCSF, GCSF, TGF, Erythropieitn, TPO, BMP, HGF, GDF, Neurotrophins, MSF, SGF, GDF.
- the skin aging comprises photoaging.
- Example of photoaging includes, but not limited to, wrinkling, scar tissue deposition, altered skin elasticity, altered skin color, altered skin texture, altered skin thickness, angioma, telangiectasia, sunburn, dryness, itchiness, neoplasia and precancerous growth.
- the preventing or improving treating skin aging comprises one or more of the following effects: alleviating skin photoaging, diminishing skin wrinkles, improving skin elasticity, improving skin firmness, or improving skin’s radiance, luminosity, or texture.
- the composition improves skin’s radiance, luminosity, or texture, and rarely produces skin irritation.
- the composition is prepared in any one formulation selected from the group consisting of a skin lotion, a skin softener, a skin toner, a skin cream, a sunscreen, an essence, a mask pack, a mask sheet, a soap, a shampoo, a cleaning foam, a cleaning lotion, a cleaning cream, an ointment, a gel and a massage cream.
- Another aspect of the invention relates to a method for preventing or improving skin aging in a subject, comprising topically applying the composition, comprising at least one compound selected from the group consisting of ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof, to an area of the skin.
- ergothioneine an analog or derivative thereof, or a dermatologically acceptable salt thereof, is present in an amount ranging from 0.01 to 20 %by weight (w/w) , 0.01 to 15 %by weight (w/w) , or 0.01 to 12%by weight (w/w) .
- the subject is human.
- ergothioneine is L ⁇ ergothioneine.
- the skin aging comprises photoaging.
- the preventing or improving treating skin aging comprises one or more of the following effects: alleviating skin photoaging, diminishing skin wrinkles, improving skin elasticity, improving skin firmness, or improving skin’s radiance, luminosity, or texture. In some particular embodiments, the preventing or improving treating skin aging comprises one or more of the following effects: improving skin’s radiance, luminosity, or texture, and rarely produces skin irritation.
- a further aspect of the invention relates to use of ergothioneine in manufacturing a composition capable of treating skin photoaging.
- Figure 1 depicts the change of Methylobacterium ⁇ Methylorubrum after 12 ⁇ week's treatment of Ergothioneine.
- compositions comprising at least one compound selected from the group consisting of ergothioneine, an analog or derivative thereof, or a dermatologically acceptable salt thereof; as well as methods for preventing or treating skin aging, comprising topical application of the composition of the invention to an area of skin.
- the composition can be prepared in a variety of forms, such as a skin lotion, a skin softener, a skin toner, a skin cream, a sunscreen, an essence, a mask pack, a mask sheet, a soap, a shampoo, a cleaning foam, a cleaning lotion, a cleaning cream, an ointment, a gel, and a massage cream.
- the term “or” is meant to include both “and” and “or” . In other words, the term “or” may also be replaced with “and/or. ”
- the term “at least” followed by a number is used to denote the start of a range beginning with that number.
- the term “comprise” or “include” and their conjugations refer to a situation where said terms are used in their non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. It also encompasses the more limiting verb ‘to consist essentially of’a nd ‘to consist of’ .
- the term “subject” or “patient” is used interchangeably and as used herein mean any mammal including but not limited to human beings including a human patient or subject to which the compositions of the invention can be administered.
- the term “mammals” include human patients and non ⁇ human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals.
- the term “treat” , “treating” or “treatment” and the like as used herein, refers to any indicia of success in the prevention or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a subject's physical or mental well ⁇ being.
- the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neurological examination, and/or psychiatric evaluations. Accordingly, the term “treating” or “treatment” includes the administration of L ⁇ Ergothioneine which may be in combination with other compounds or agents.
- the terms “improving” and the like are used generally to mean improving or alleviating it or its symptoms partially in the subject, such as alleviating skin photoaging, diminishing skin wrinkles, improving skin elasticity, improving skin firmness, or improving skin’s radiance, luminosity, or texture.
- preventing, ” “prevention, ” and the like are used generally to mean preventing or inhibiting deterioration or further deterioration of the visual system of an aging subject, as compared with a comparable visual system not receiving the synthetic retinal derivative.
- the term “effective amount” refers to an amount that is required to improve at least one symptom of a medical condition in an individual.
- a "cosmetic" can be contacted with the skin, such as by being rubbed, poured, sprinkled, or sprayed on the skin or otherwise introduced into or onto the skin, and is intended to improve the aesthetic appearance of the skin, such as by cleaning, beautifying, promoting attractiveness, or altering, e.g., improving, the aesthetic appearance of the contacted skin.
- a cosmetic benefit is typically visual or aesthetic, and can be evaluated using subjective or objective assays.
- topical application means directly laying on or spreading on the skin, hair, or nail, e.g., by use of the hands or an applicator such as a wipe.
- the term "dermatologically acceptable” is used to refer to compounds and compositions that retain biological effectiveness and which are suitable for use in contact with the skin or hair of humans and lower animals without undue toxicity, incompatibility, instability, irritation, allergic response, and the like.
- subjects will be randomly assigned to use 0.01 ⁇ 12%ergothioneine moisturizer of the invention to the right or left face and the bland moisturizer to the opposite face. Neither the subjects nor the investigator will know the identity of the creams. The study coordinator will develop and maintain the study blind. Subjects will be dispensed a diary to record daily use of the moisturizers, provided a return schedule, and asked to return to the research center at week 4, 8 and 12. On each return (check point) , the enrolled subjects will complete baseline efficacy and tolerability assessments separately for each side of the face. The skin elasticity and corneometry measurements will be made and recorded from both sides of the face. Additionally, at week 8 and 12, ten randomly selected subjects will participate in the photography substudy.
- VISIA ⁇ CR images will be taken of the front, right, and left face with standard lighting 1 at baseline and week 12 in both jpeg and CR2 raw files for image analysis at a later date. Furthermore, at week 12 (the study endpoint) , both sides of the face are swabbed for microbiome analysis. Subject diaries will be checked for compliance and collected.
- Noninvasive assessments skin elasticity and corneometery hydration measurements will be made and recorded from both the right and left cheek at baseline, week 4, week 8, and week 12 (Data will be recorded in the Table below) .
- Microbiome swabbing Both sides of the face will be swabbed for microbiome analysis at baseline and week 12. Two swabs will be generated per visit for a total of 4 swabs per subject. Swabs will be stored in the –80°C freezer until the end of the study for shipping (on dry ice) to a commercial laboratory in Vancouver, Canada for microbiome quantitative profiling . 120 swabs will be shipped at the end of study for analysis.
- ⁇ STEP 1 Dip a fresh swab in molecular grade DNA free water. With one hand, stretch the skin site taut. With the other hand, hold the swab so the shaft is parallel to the skin surface. Apply firm pressure and rub the swab back and forth rigorously 50 times (for 30 seconds) rotating the swab slowly while swabbing.
- ⁇ STEP 2 Carefully return the swab to the tube, ensuring that neither the swab, the swab stick nor the vessel touch any surface.
- ⁇ STEP 3 Place the tube into a biospecimen bag and freeze at ⁇ 80°C until ready to ship.
- the intensity or severity of an AE is characterized as:
- Moderate AE sufficiently discomforting to interfere with daily activity.
- AE occurs following the application of the study product and it cannot be reasonably explained by any other known characteristics of the subject’s clinical state, environmental or toxic factors, or other modes of therapy administered to the subject. It disappears or decreases upon discontinuation of the study product and reappears on a re ⁇ challenge of the study product. This is necessary to evaluate allergic or irritant contact dermatitis.
- a Wilcoxon signed rank test is used for analysis of all ordinal nonparametric data as compared to baseline.
- a Student’s T ⁇ test is used to analyze all parametric numerical elasticity and corneometry data.
- An outside lab will analyze the data from the facial swabs. Statistical significance is defined as p value less than or equal to 0.05.
- a topical composition comprising ergothioneine was prepared.
- the amounts of each component of the compositions are given as percentages of each component’s weight relative to the total weight of the composition.
- the formulation comprises 0.01 to 12 % (w/w) ergothioneine, and one or more additives selected from Hyaluronic Acid (0.1 ⁇ 3%) , Retinol/Retinoic acid (0.1 ⁇ 2%) , Hydrolyzed Collagen/Collagen Peptides (0.1 ⁇ 3%) , Vitamin C (0.1 ⁇ 6%) , Vitamin E (0.1 ⁇ 10%) , Cannabidiol (0.1 ⁇ 5%) , EGCG/Green tea (0.1 ⁇ 10%) , Polyhydroxy Acids (0.1 ⁇ 12%) , Glycolic Acid (0.1 ⁇ 10%) , Aloe vera (0.1 ⁇ 10%) , Niacinamide (0.1 ⁇ 10%) , Resveratrol (0.1 ⁇ 5%) , Superoxide dismutase (0.1 ⁇ 5%) , Tea tree oil (0.1 ⁇ 10%) , Bakuchiol (0.1 ⁇ 5%) , Grapeseed oil (0.1 ⁇ 10%) , Petroleum jelly (0.1 ⁇ 5%) , or squalene (0.1 ⁇ 10%) (w/w)
- the primary efficacy endpoint was met at week 4 for luminosity and radiance and week 8 for radiance, luminosity, and texture.
- the safety endpoint was the absence of significant adverse reactions. The safety endpoint was met.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne, entre autres, une composition topique destinée à prévenir ou traiter le vieillissement cutané, comprenant au moins un composé choisi dans le groupe constitué par l'ergothionéine, un analogue ou un dérivé de celle-ci, ou un sel de qualité dermatologique de celle-ci. Cette composition topique améliore l'éclat, la luminosité ou la texture de la peau, et ne provoque que rarement des irritations cutanées. Selon un autre aspect, la présente invention concerne un procédé de prévention ou de traitement du photovieillissement chez un sujet, comprenant l'application topique de la composition de l'invention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202380007853.5A CN116390722A (zh) | 2022-01-28 | 2023-01-16 | 预防或改善皮肤老化的方法和组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022074500 | 2022-01-28 | ||
CNPCT/CN2022/074500 | 2022-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023143184A1 true WO2023143184A1 (fr) | 2023-08-03 |
Family
ID=87470547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/072356 WO2023143184A1 (fr) | 2022-01-28 | 2023-01-16 | Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023143184A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2281799A1 (fr) * | 1997-02-20 | 1998-08-27 | Oxis International, Inc. | Procedes et compositions servant a proteger les mitochondries |
CN105982890A (zh) * | 2014-09-05 | 2016-10-05 | 中国医药大学 | 麦角硫因应用于活化细胞的Nrf2信号通路的用途 |
CN110917061A (zh) * | 2019-12-26 | 2020-03-27 | 华熙生物科技股份有限公司 | 一种含麦角硫因提取液、糙米发酵滤液和乙酰壳糖胺的组合物及其应用 |
CN113648236A (zh) * | 2021-08-26 | 2021-11-16 | 上海拜思丽实业有限公司 | 一种抗氧化组合物、抗氧化化妆品组合物及其制备方法 |
-
2023
- 2023-01-16 WO PCT/CN2023/072356 patent/WO2023143184A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2281799A1 (fr) * | 1997-02-20 | 1998-08-27 | Oxis International, Inc. | Procedes et compositions servant a proteger les mitochondries |
CN105982890A (zh) * | 2014-09-05 | 2016-10-05 | 中国医药大学 | 麦角硫因应用于活化细胞的Nrf2信号通路的用途 |
CN110917061A (zh) * | 2019-12-26 | 2020-03-27 | 华熙生物科技股份有限公司 | 一种含麦角硫因提取液、糙米发酵滤液和乙酰壳糖胺的组合物及其应用 |
CN113648236A (zh) * | 2021-08-26 | 2021-11-16 | 上海拜思丽实业有限公司 | 一种抗氧化组合物、抗氧化化妆品组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
LI, YI QUN; ZHOU, NIAN-BO: "Ergothioneine biological function and major applications", FOOD ENGINEERING, CN, no. 3, 30 September 2010 (2010-09-30), CN , pages 26 - 28, XP009547878, ISSN: 1673-6044 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
JP4745608B2 (ja) | 電子伝達剤のリン酸誘導体を用いた皮膚治療 | |
CN111973641B (zh) | 去头屑组合物和其使用方法 | |
AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
EP3393488B1 (fr) | Composition comprenant un extrait d'ambora et un extrait de thé vert pour le traitement du psoriasis, de la dermatite atopique, de l'urticaire chroniques, du prurit resistant aux antihistaminiques et du prurit senile | |
CN110325246B (zh) | 防晒组合物 | |
CN111700853A (zh) | 一种具有抗敏修复功效的化妆品组合物及其应用 | |
US20170209349A1 (en) | Topical skin care composition for night use | |
US11241374B2 (en) | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride | |
WO2023143184A1 (fr) | Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau | |
US20150164967A1 (en) | Personal Care Products Containing Extracts of Rosemary | |
US20100104673A1 (en) | Methods and Compositions for Treatment of Skin Conditions | |
US11400038B2 (en) | Synergistic antioxidant compositions | |
CH700735B1 (de) | Kosmetische Komposition für die Verjüngung des Erscheinungsbildes der Haut. | |
CN116390722A (zh) | 预防或改善皮肤老化的方法和组合物 | |
US20230140298A1 (en) | Topical composition comprising retinol and pdrn and use of same | |
CN115209887A (zh) | Ppar激动剂复合物及其使用方法 | |
CA2542861A1 (fr) | Methodes de traitement de troubles dermiques inflammatoires non microbiens | |
KR20240093957A (ko) | 레티놀 및 pdrn을 포함하는 국소 조성물 및 이의 용도 | |
Sahoo et al. | Rôle of methylchloroisothiazolinone/methylisothiazolinone (Kathon [sup®] CG) in poikiloderma of Civatte. | |
Wolf et al. | An alpha hydroxy acid derivative suitable for sensitive skin | |
US20230346677A1 (en) | Topical compositions containing vitamin c | |
US20230346678A1 (en) | Topical compositions containing vitamin c | |
WO2023209655A1 (fr) | Composition améliorant l'énergie des cellules cutanées | |
US20210030647A1 (en) | Regenerating composition with smoothing action for treating skin imperfections and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23746066 Country of ref document: EP Kind code of ref document: A1 |